Are There Any Marijuana Stocks to Buy in September?
Motley Fool Staff - Motley Fool - Sun Sep 21, 12:07PM CDT
Marijuana stocks have been an area of tremendous investor excitement -- and tremendous risk. In fact, some people have argued So the big question, then, is this: are there any marijuana stocks worth buying? We asked some of our top analysts for their...
Cannabis Technologies Looks to Diversify Pipeline with New Hire
ACCESSWIRE - Thu Sep 18, 8:56AM CDT
WHITEFISH, MT / September 18, 2014 / Cannabis Technologies Inc. (OTC: CANLF) (TSX-V: CAN), a biopharmaceutical drug discovery and development company focused on the pharmacology and therapeutic potential of cannabinoids (CBDs), recently announced the appointment of Peter Huang as its Senior Bioinformatician. The move could unlock shareholder value by broadening its pipeline over the coming years.
Critical Alerts For GT Advanced Technologies, INSYS Therapeutics, Auxilium Pharmaceuticals, NQ Mobile and Potbelly Released By InvestorsObserver
PR Newswire - Thu Sep 18, 8:31AM CDT
InvestorsObserver issues critical PriceWatch Alerts for GTAT, INSY, AUXL, NQ and PBPB.
Opium (Opioid) Addiction - Pipeline Review, H2 2014 - 19 Drug Profiles from 13 Companies
M2 - Tue Sep 09, 6:03AM CDT
Research and Markets (http://www.researchandmarkets.com/research/76t4hq/opium_opioid) has announced the addition of the "Opium (Opioid) Addiction - Pipeline Review, H2 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Opium (Opioid) Addiction, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Opium (Opioid) Addiction and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Involved in Therapeutics Development - Alkermes Plc - Nanotherapeutics, Inc. - Acura Pharmaceuticals, Inc. - Catalyst Pharmaceutical Partners, Inc. - INSYS Therapeutics, Inc. - Camurus AB - Omeros Corporation - D&A Pharma SAS - Reckitt Benckiser Pharmaceutical, Inc. - AllTranz, Inc. - Relmada Therapeutics, Inc. - Celtic Pharmaceutical Holdings L.P. - Foresee Pharmaceuticals, LLC Drug Profiles - TA-CD - buprenorphine hydrochloride - RBP-6300 - Cannabidiol - OMS-405 - MAL - samidorphan - (buprenorphine hydrochloride naloxone hydrochloride) - CPP-115 - OMS-527 - buprenorphine hydrochloride ER - Vaccine for Opium Addiction - Cannabidiol - FP-004 - methadone IR - buprenorphine hydrochloride - Synthetic Peptides to Activate DOR and MOR and Inhibit MRP-1 for Oncology and Morphine Addiction - Synthetic Peptides to Inhibit Mu Opioid, Delta Opioid and MRP-1 for Oncology and Morphine Addiction - naltrexone For more information visit http://www.researchandmarkets.com/research/76...ium_opioid
Insys Therapeutics, Inc. Named Arizona Bioscience Company of the Year
Business Wire - Wed Sep 03, 7:01AM CDT
In recognition of its innovation on behalf of patients, investments in product line development, and its rapidly escalating growth, Insys Therapeutics, Inc., of Chandler, Arizona, was named the 2014 Arizona Bioscience Company of the Year by the Arizona Bioindustry Association (AZBio).
From Innovation to Investment: Arizona Bioscience Week Has Something for Everyone
Business Wire - Tue Sep 02, 10:53PM CDT
Arizona is home to one of the fastest growing biotech sectors in the country with over 1300 life science companies. Recent industry successes include the top performing IPO of 2013 (Insys Therapeutics, Inc.) and the 2014 acquisition of Ulthera for $600M. Arizona researchers have contributed to the development of the drug that saved the lives of two health workers infected with the Ebola virus, designed and built revolutionary cardiac medical devices, pioneered new diagnostics and cancer therapies, and a wealth of other life science innovations that are benefiting patients here at home and around the world.
Insys Therapeutics' Cannabidiol Gets Orphan Drug Status - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Tue Aug 26, 3:30PM CDT
Insys Therapeutics (INSY) announced that the FDA has granted orphan drug status to its pharmaceutical cannabidiol (CBD), for the treatment of glioblastoma multiforme (GBM).
Insys Therapeutics to Present at Morgan Stanley Global Healthcare Conference 2014
Marketwire - Tue Aug 26, 6:02AM CDT
Insys Therapeutics, Inc. (NASDAQ: INSY) today announced that the company will present at the Morgan Stanley Global Healthcare Conference 2014 to be held September 8-10, 2014 at the Grand Hyatt New York.
FDA names potential Insys treatment an orphan drug
By The Associated Press - AP - Mon Aug 25, 9:17AM CDT
A potential treatment from Insys Therapeutics Inc. for an aggressive form of brain cancer will have some marketing exclusivity if regulators eventually approve it.
Insys Therapeutics Receives FDA Orphan Drug Designation for Its Pharmaceutical Cannabidiol as a Potential Treatment for Glioblastoma Multiforme
Marketwire - Mon Aug 25, 6:00AM CDT
Insys Therapeutics, Inc. (NASDAQ: INSY), a specialty pharmaceutical company that is developing and commercializing innovative drugs and novel drug delivery systems, today announced that the U.S. Food and Drug Administration (FDA) has granted orphan drug designation (ODD) to its pharmaceutical cannabidiol (CBD) for the treatment of glioblastoma multiforme (GBM), the most common and most aggressive malignant primary brain tumor in humans.
5 Stocks Jumping on Unusual Volume
at The Street - Tue Aug 19, 5:30AM CDT
Often when above-average volume moves into an equity, it precedes a large spike in volatility.
Insys' Q2 sales nearly triple
at Investor's Business Daily - Tue Aug 12, 5:42PM CDT
The cancer pain treatments maker said revenue jumped 196% to $55.7 mil, beating estimates for $52.8 mil, largely on higher sales of its fast-acting, short-duration Subsys sublingual spray, often used to treat patients prior to procedures. EPS was 26...
Nasdaq stocks posting largest percentage increases
AP - Tue Aug 12, 12:48PM CDT
NEW YORK (AP) — A look at the 10 biggest percentage gainers on Nasdaq at 1 p.m.:
Stocks Stake Out Thin Gains; Intercept, Insys, Autohome Gain
at Investor's Business Daily - Tue Aug 12, 9:53AM CDT
Stocks did note venture far from their opening levels early Tuesday. The Nasdaq, S&P 500 and the Dow Jones industrial average all rose about 0.1%. Volume was mixed, up 3% on the Nasdaq and 24% lower on the NYSE, compared with trade early Monday. The...
Stock Futures Hem And Haw; Intercept Pharmaceuticals Soars
at Investor's Business Daily - Tue Aug 12, 8:07AM CDT
Stock futures were indecisive early Tuesday, easing from narrow gains into mixed trade. Dow futures reversed to trade 3 points below fair market value. Nasdaq 100 futures kept a fraction gain. S&P 500 futures held 1.1 points into positive territory....
Insys Therapeutics Submits NDA for Its New Oral Formulation of Dronabinol
Marketwire - Tue Aug 12, 6:34AM CDT
Insys Therapeutics, Inc. (NASDAQ: INSY), a specialty pharmaceutical company that is developing and commercializing innovative drugs and novel drug delivery systems, today announced it has submitted a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) for its proprietary Dronabinol Oral Solution for anorexia associated with weight loss in patients with AIDS; and nausea and vomiting associated with cancer chemotherapy in patients who have failed to respond adequately to conventional antiemetic treatments. Dronabinol Oral Solution is an orally administered liquid formulation of the pharmaceutical cannabinoid dronabinol, a synthetic version of tetrahydrocannabinol (THC).
Insys Therapeutics Reports Second Quarter 2014 Results
Marketwire - Tue Aug 12, 5:50AM CDT
Insys Therapeutics, Inc. (NASDAQ: INSY) today announced its financial results for the three-month period ended June 30, 2014. Second quarter 2014 highlights include:
Cannabis Should Be Treated as an Agricultural Commodity, Not a Biotech Investment
ACCESSWIRE - Mon Aug 11, 1:44PM CDT
Pittsburgh, PA / August 11, 2014 / While the future of cannabusiness is certainly bright, one controversial yet crucial caveat must be made. Pot stocks should be treated as an agricultural commodity investment rather than as a biotech investment. This is not to say that cannabis cannot be used as a pharmaceutical. It certainly can. Rather it should not be invested in as one would invest in a pharmaceutical. Taking a biotech strategy with pot stocks is the wrong road to take.
5 Stocks Set to Soar on Bullish Earnings
at The Street - Mon Aug 11, 1:36PM CDT
These heavily shorted stocks could get squeezed much higher if they report bullish earnings today.
Insys Therapeutics to Report Second Quarter 2014 Results
Marketwire - Tue Jul 29, 7:03AM CDT
Insys Therapeutics, Inc. (NASDAQ: INSY) today announced that the Company will release its financial results for the second quarter 2014 on Tuesday, August 12, 2014, before the U.S. financial markets open.